CIK: 0001637359 · Show all filings
Period: Q1 2020 (← Previous) (Next →)
Filing Date: May 14, 2020
Total Value ($000): $241,630 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| REPL | Replimune Group | 5,323,455 | $52,825 | 21.9% | $17.40 | -14.3% | Common Stock | 76029N106 |
| — | Morphic Holding | 2,969,582 | $43,593 | 18.0% | $19.82 | — | Common Stock | 61775R105 |
| GOSS | Gossamer Bio | 4,275,726 | $43,399 | 18.0% | $20.85 | -37.4% | Common Stock | 38341P102 |
| ARQT | Arcutis Biothereapeutics | 844,680 | $25,171 | 10.4% | $26.87 | 0.0% | Common Stock | 03969K108 |
| — | Translate Bio | 2,437,603 | $24,303 | 10.1% | $12.65 | — | Common Stock | 89374L104 |
| IMUX | Immunic | 1,371,494 | $8,298 | 3.4% | $13.14 | -38.8% | Common Stock | 4525EP101 |
| — | Paratek Pharmaceuticals | 2,600,410 | $8,191 | 3.4% | $34.18 | — | Common Stock | 699374302 |
| — | ESSA Pharma | 1,689,848 | $6,759 | 2.8% | $3.14 | — | Common Stock | 29668H708 |
| BEAM | Beam Therapeutics | 302,821 | $5,451 | 2.3% | $21.73 | 0.0% | Common Stock | 07373V105 |
| — | Cidara Therapeutics | 2,008,150 | $4,980 | 2.1% | $5.64 | — | Common Stock | 171757107 |
| — | FibroGen | 130,646 | $4,540 | 1.9% | $27.34 | — | Common Stock | 31572Q808 |
| TRVI | Trevi Therapeutics | 1,263,408 | $4,157 | 1.7% | $8.61 | -47.0% | Common Stock | 89532M101 |
| — | Prevail Therapeutics | 272,807 | $3,326 | 1.4% | $13.20 | — | Common Stock | 74140Y101 |
| — | Jounce Therapeutics | 529,965 | $2,517 | 1.0% | $21.99 | — | Common Stock | 481116101 |
| — | ObsEva | 999,364 | $2,408 | 1.0% | $9.76 | — | Common Stock | H5861P103 |
| — | Pieris Pharmaceuticals | 750,741 | $1,712 | 0.7% | $1.83 | — | Common Stock | 720795103 |